Results from two clinical trials indicate that NEXIUM (esomeprazole magnesium) can reduce the incidence of gastric (stomach) ulcers in patients at risk of developing gastric ulcers and who regularly take either non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs.

NSAIDs are a class of pain relief medications that include traditional, non-selective drugs, such as ibuprofen, naproxen and aspirin, and newer COX-2- selective agents. Non-selective NSAIDs are known for increasing the risk of gastric ulcers, particularly among older patients who take them regularly or who have a history of gastric ulcers.

Pooled data from the double-blind, randomized, six-month trials showed that significantly fewer patients taking either NEXIUM 20 mg or NEXIUM 40 mg, in addition to their regular non-selective NSAID/COX-2-selective therapy, developed an ulcer at six months, compared to those taking a placebo (5.2 percent and 4.6 percent, respectively, vs. 17 percent, p<0.001).(1) These differences were seen as early as the first month of treatment and maintained throughout the study duration.(1)

“Paradoxically, NSAID use is common among patients at high risk for gastric ulcers or other complications associated with these medications. Although COX-2-selective drugs generally cause fewer gastric ulcers than non- selective NSAIDs, these events aren’t completely eliminated, and the residual side-effect rate still may be high,” said James M. Scheiman, MD, Division of Gastroenterology, Department of Internal Medicine, University of Michigan. “Data from the two trials showed that NEXIUM was effective in reducing stomach ulcers in at-risk patients who require chronic NSAID treatment.”

In the first trial, known as Verification of Esomeprazole for NSAID Ulcers and Symptoms (VENUS), a significantly smaller percentage of patients taking NEXIUM 20 mg or 40 mg developed a gastric or duodenal (occurring in the beginning of the small intestine) ulcer, compared to patients on placebo (5.3 percent and 4.7 percent, respectively, versus 20.4 percent, p<0.001 and p<0.0001).(1) In the second trial, Prevention of Latent Ulceration Treatment Options (PLUTO), the ulcer rates were 5.2 and 4.4 percent for patients on NEXIUM 20 mg and 40 mg, respectively, versus 12.3 percent for those on placebo (p=0.018 and p=0.007).(1)

Tags: esomeprazole magnesium, gastric ulcers, Nexium, stomach ulcers

This entry was posted on Friday, March 20th, 2009 at 7:42 am and is filed under Pain killers. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.